The agreement adds Atherotech’s cardiometabolic testing services, including the patented VAP (Vertical Auto Profile) advanced lipid profile, to SpringFire’s offering.
Jim McClintic, managing partner of SpringFire Laboratory Network, said high complexity laboratories such as Atherotech are in great demand in the clinical trials market. They offer rapid turnaround times, competitive pricing and professional consultation on protocol development with clinical trials experience.
Atherotech offers researchers more than 50 cardiovascular and metabolic tests and is the only laboratory that performs the VAP Cholesterol Test, a directly measured assessment of all major lipoprotein classes (HDL, LDL, VLDL, IDL and Lp(a)) and their important subclasses, including HDL2, HDL3, LDL1-LDL4, apoB, apoA1 and the apoB/apoA1 ratio. The VAP profile also provides LDL subclass pattern (A, A/B or B) and remnant lipoprotein cholesterol.
“This partnership will further expose the VAP Test to the clinical trial marketplace,” said Michael Mullen, CEO of Atherotech.
With a combined menu of more than 1,000 specialty tests, SpringFire offers sponsors and CROs expertise and testing services in numerous therapeutic areas, including anatomical pathology, molecular genetics and women’s health.
